

## TABLE OF CONTENTS

|                                                                                                                |          |
|----------------------------------------------------------------------------------------------------------------|----------|
| <b>SUMMARY OF PETITIONERS' ARGUMENT .....</b>                                                                  | <b>1</b> |
| <b>PETITIONERS.....</b>                                                                                        | <b>6</b> |
| <b>EMERGENT FACTS: .....</b>                                                                                   | <b>9</b> |
| A.    ALS is a Vastly Heterogeneous, Terminal Rare Disease .....                                               | 9        |
| 1.    Cellular Heterogeneity .....                                                                             | 11       |
| 2.    Genetic Heterogeneity .....                                                                              | 11       |
| 3.    Heterogeneity by Age of ALS Onset .....                                                                  | 13       |
| 4.    Heterogeneity by Speed of Progression.....                                                               | 13       |
| 5.    Heterogeneity by Site of ALS Onset .....                                                                 | 15       |
| B.    ALS Lifespan and Dying Motor Neurons.....                                                                | 18       |
| C.    New Emergent Evidence of Long-Term Survival Data in NurOwn Phase 3 Trial and EAP.....                    | 19       |
| 1.    Survival Data is the Gold Standard for Efficacy .....                                                    | 19       |
| 1.    People in EAP had a 5.5 Month Improvement in OS vs. Matched Controls .....                               | 21       |
| 2.    EAP's 100% Five-Year Survival Data Exceeds 20% Anticipated Survival<br>Data in ALS Natural History ..... | 23       |
| 3.    Standardized Mortality Ratio: Five-Year EAP Data.....                                                    | 25       |
| 4.    New Trach-free Survival Data Far Exceeds Median ALS Natural History .....                                | 26       |
| 5.    Improved Survival - by Site of Onset .....                                                               | 28       |
| 6.    Improved Survival - Bulbar Onset Subgroup .....                                                          | 29       |
| 7.    Improved Survival - Limb Onset Subgroup.....                                                             | 33       |
| D.    Emergent Evidence of Improvement in Respiratory Function.....                                            | 34       |
| 1.    The Phrenic Nerve and Neurotrophic Factors Impact Respiratory Function .....                             | 34       |
| 2.    Measuring Respiratory Function as a Predictor of ALS Survival .....                                      | 35       |
| 3.    Preserved and Improved Respiratory Function in NurOwn Trial and EAP Recipients .....                     | 37       |
| a.    Time-to-NIV .....                                                                                        | 37       |
| b.    Real World Evidence of Improved Respiratory Function .....                                               | 39       |
| 4.    NurOwn Improved Matt Bellina's Respiratory Function when<br>He Received 7 Doses via Right to Try .....   | 41       |

|    |                                                                                                                                                                                                                  |    |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| E. | Emergent Data of Significant Reduction in Harmful Neurofilament Light in EAP Participants who Received Additional Doses of NurOwn .....                                                                          | 43 |
| F. | Other Emergent Data from EAP .....                                                                                                                                                                               | 44 |
| 1. | New Evidence of Progression-free Survival (PFS).....                                                                                                                                                             | 45 |
| 2. | 75-85% Slowing in Long-term Rate of Decline .....                                                                                                                                                                | 45 |
| G. | RWE from Ten People in EAP and One Person in Right to Try Resulted in Unprecedented Proof that Can Meet the “Substantial Evidence” Threshold as Multiple Unprecedented and Probative “n of 1” Stories Exist..... | 46 |

## **FACTUAL BACKGROUND.....50**

|    |                                                                                                                                                                              |    |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| A. | Subjective ALSFRS-R is the Patient-Reported Bounded Scale Used for ALS Clinical Trial Endpoints .....                                                                        | 50 |
| B. | Limitations in the ALSFRS-R are Impacting Trial Endpoints and Drug Approvals.....                                                                                            | 51 |
| 1. | Floor Effect is the Scale’s Inability to Measure Changes once an ALSFRS-R Sub-domain Score is Zero, Making it Falsely Appear as if People are Stabilizing. ....              | 54 |
| 2. | Non-Dominant Hand Onset Creates a Ceiling Effect that Can “Mislead” Clinicians about Progression in the Fine Motor Skills Domain.....                                        | 55 |
| 3. | Ceiling Effect in Participants with Non-dominant Hand Onset Likely Impacted the NurOwn Trial Outcome – especially in the Pre-specified Subgroups of ALSFRS-R $\geq 35$ ..... | 57 |
| C. | Understanding Trial Endpoints: What Constitutes a “Clinically Meaningful” Change in ALS Decline? .....                                                                       | 59 |
| 1. | People with ALS on What is Clinically Meaningful .....                                                                                                                       | 60 |
| 2. | Clinicians on What is Clinically Meaningful .....                                                                                                                            | 62 |
| 3. | Understanding NurOwn’s Primary Endpoint of -1.25 point Change in Slope .....                                                                                                 | 63 |
| D. | NurOwn’s Phase 3A Trial Design – in the US.....                                                                                                                              | 65 |
| 1. | NurOwn Trial - Genetics .....                                                                                                                                                | 65 |
| 2. | NurOwn Trial Design and Qualifications .....                                                                                                                                 | 66 |
| E. | NurOwn’s Phase 3A Trial Results - Totality of the Evidence Supports Approval .....                                                                                           | 67 |
| 1. | FDA’s Position - NurOwn Trial Didn’t Meet Primary or Secondary Endpoints.....                                                                                                | 67 |
| 2. | Totality of Evidence - NurOwn Works on Some.....                                                                                                                             | 68 |
| a. | NurOwn Met Pre-specified Secondary Endpoint ALSFRS-R $\geq 35$ .....                                                                                                         | 69 |

|    |                                                                                                                                                                                                                         |     |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| b. | Totality of Evidence Demonstrated a Clinically Meaningful and Consistent Impact in the Early Progression Subgroup of ALSFRS-R $\geq 35$ .....                                                                           | 69  |
| c. | Statistically Significant Temporal Treatment Effect Over Multiple Endpoints .....                                                                                                                                       | 70  |
| d. | Statistically Significant Temporal Treatment Effect Over Multiple ALSFRS-R Domains.....                                                                                                                                 | 71  |
| e. | NurOwn Met Endpoints for Subgroup of People Earlier in Progression – Those without a Floor Effect .....                                                                                                                 | 72  |
| f. | Post Hoc Analysis showed that NurOwn Demonstrated a Clinically Meaningful and Consistent Impact in the Early Progression Subgroup of ALSFRS-R $\geq 27$ .....                                                           | 75  |
| 3. | At 28 weeks, NurOwn’s Results were nearly 2x Larger than Tofersen’s Results .....                                                                                                                                       | 78  |
| 4. | In the Early Progression Subgroup, the NurOwn Data Corroborated the Clinical Observations of Trial PIs, Trial Participants and their Treating Neurologists who Testified that NurOwn Halted Lethal ALS Progression..... | 80  |
| F. | NurOwn’s Expanded Access Program Provided Dosing & Durability Data, along with Unprecedented Survival Data.....                                                                                                         | 83  |
| G. | NurOwn’s Phase 2b Trial – in the US.....                                                                                                                                                                                | 84  |
| 1. | Statistical Results of Phase 2 Trial .....                                                                                                                                                                              | 85  |
| a. | Overall Phase 2 Trial Results .....                                                                                                                                                                                     | 85  |
| b. | Results of Fast Progressors.....                                                                                                                                                                                        | 86  |
| c. | Inconsistent Acceptance of Efficacy Data of Subgroups of People with Fast Progressing ALS.....                                                                                                                          | 87  |
| H. | NurOwn Phase 3 Petitioners with Real-World Evidence.....                                                                                                                                                                | 91  |
| 1. | Matt Klingenberg - Phase 3 .....                                                                                                                                                                                        | 91  |
| 2. | Eric Stevens – Phase 3 .....                                                                                                                                                                                            | 94  |
| 3. | Josh Smith - Phase 3 .....                                                                                                                                                                                              | 99  |
| 4. | Estate of Roberto Muggli - Phase 3 - ( Dec 2, 1974 - May 2, 2023).....                                                                                                                                                  | 105 |
| 5. | Estate of Kade Simons - Phase 3 - (Aug 10, 1997 - August 4, 2024).....                                                                                                                                                  | 107 |
| 6. | Lesley Krummel - Phase 3.....                                                                                                                                                                                           | 112 |
| 7. | Estate of Justin Rogers - Phase 3 - (Jan 15, 1984 - June 15, 2023).....                                                                                                                                                 | 115 |

|    |                                                                                                                             |     |
|----|-----------------------------------------------------------------------------------------------------------------------------|-----|
| I. | Real-world Evidence from NurOwn Phase 2 Recipients - 2015 .....                                                             | 120 |
| 1. | Petitioner Terri Pickering Saenz .....                                                                                      | 120 |
| 2. | Phase 2 NurOwn Trial Participants who Stabilized and Improved.....                                                          | 123 |
| a. | Mike Cimbura Improved but Died Waiting for FDA .....                                                                        | 123 |
| b. | Bobby Forster Improved .....                                                                                                | 126 |
| c. | Phase 2 Placebo.....                                                                                                        | 127 |
| J. | Matt Bellina Regained Function after receiving NurOwn via the Right to Try Law. ....                                        | 128 |
| K. | Veterans with ALS who couldn't get Access to NurOwn.....                                                                    | 134 |
| 1. | Petitioner Nick Warack.....                                                                                                 | 134 |
| 2. | Veterans have a Heightened Risk of ALS.....                                                                                 | 136 |
| L. | Other Petitioners who couldn't get Access to NurOwn .....                                                                   | 139 |
| 1. | Petitioner Shahriar Minokadeh, MD .....                                                                                     | 139 |
| 2. | Petitioner Mayuri Saxena .....                                                                                              | 142 |
| 3. | Petitioner Patricia Manhardt.....                                                                                           | 145 |
| 4. | Petitioner Jamie Rose Berry .....                                                                                           | 147 |
| 5. | Petitioner Tara Collazo .....                                                                                               | 151 |
| a. | NurOwn Trial - Did Not Qualify .....                                                                                        | 151 |
| b. | Non-Dominant Hand Onset May Have Impacted CNM-Au8 OLE Outcome.....                                                          | 152 |
| c. | Floor Effect Example.....                                                                                                   | 153 |
| d. | Pridopidine EAP has been Life-Changing.....                                                                                 | 153 |
| M. | Biomarker Data is Supporting Evidence of Efficacy and Reasonably Likely<br>to Predict a Clinically Meaningful Benefit ..... | 156 |
| 1. | CSF Biomarkers Demonstrate Target Engagement .....                                                                          | 157 |
| a. | Dr. Bowser's Presentation at 2023 AdComm.....                                                                               | 158 |
| b. | Dr. Brown's 2021 Presentation of the CSF Biomarkers.....                                                                    | 159 |
| c. | Totality of CSF Biomarkers Demonstrate a Treatment Effect and<br>Validate the Plausible Mechanism of Action.....            | 160 |
| 2. | Neurodegeneration Biomarker, Neurofilament Light in ALS .....                                                               | 161 |
| a. | Neurofilament Light, Demonstrated a Beneficial Decrease during the<br>28-week NurOwn Trial .....                            | 162 |
| b. | Neurofilament Light Shows Long-term, Beneficial Impact during EAP.....                                                      | 163 |

|    |                                                                                                                                           |     |
|----|-------------------------------------------------------------------------------------------------------------------------------------------|-----|
| c. | Repeated Dosing Creates a Long-term, Beneficial Impact on Neurodegeneration Biomarker, Neurofilament Light.....                           | 164 |
| d. | NfL Changes in NurOwn’s EAP vs. Tofersen Trial, OLE and EAP.....                                                                          | 166 |
| 3. | UNC13 Genetic Biomarker Supports Accelerated Approval .....                                                                               | 167 |
| 4. | FDA Failed to Grant RMAT Designation for Stem Cell Therapy despite Potential to Treat ALS, a Rare Disease with a Critical Unmet Need..... | 172 |
| N. | “Plausible Mechanism of Action” of Stem Cells Enhanced with Neurotrophic Factors.....                                                     | 173 |
| O. | NurOwn Drug Development and Israel’s Role in Stem Cell Innovation .....                                                                   | 176 |
| P. | NurOwn’s Phase 1/2a Trials in Israel.....                                                                                                 | 178 |
| Q. | NurOwn’s Compassionate Use Program – in Israel.....                                                                                       | 179 |
| R. | Update on the Israeli NurOwn Recipients.....                                                                                              | 180 |
| 1. | Long-term Survivors from NurOwn’s Early Trials.....                                                                                       | 180 |
| 2. | One of Dr. Bedlack’s Documented ALS “Reversals” was a NurOwn Recipient .....                                                              | 181 |
| S. | Congressional Hearings and Documentaries on Expediting ALS Drug Development, Regulatory Flexibility, Conditional Approval & Urgency ..... | 182 |
| 1. | 2000 – Senate Hearing on Stem Cells & Neurotrophic Factors.....                                                                           | 183 |
| 2. | 2000 - Jenifer Estess testified about Promising Stem Cell Research in ALS .....                                                           | 183 |
| 3. | 2016 Documentary - Die Trying: the Battle for ALS Treatments.....                                                                         | 184 |
| T. | ALS Guidance Document – PROs and Regulatory Flexibility .....                                                                             | 186 |
| U. | Procedural History.....                                                                                                                   | 186 |
| V. | NurOwn’s Phase 3B Trial Design .....                                                                                                      | 188 |
| W. | Drug Development Timeline doesn’t Match the Urgency of ALS .....                                                                          | 189 |

## **PETITIONERS’ MEMORANDUM..... 191**

|    |                                                                                      |     |
|----|--------------------------------------------------------------------------------------|-----|
| I. | NurOwn Survival Data Meets or Exceeds Outcomes of Other FDA-Approved Therapies ..... | 192 |
| A. | New Long-Term Evidence of Overall Survival and Trach-free Survival.....              | 193 |
| 1. | NurOwn’s Survival Data Beats Riluzole and Radicava.....                              | 193 |
| a. | Riluzole .....                                                                       | 193 |
| b. | Radicava .....                                                                       | 194 |

|     |                                                                                                                                                                                                                                                        |     |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| B.  | NurOwn Evidence Exceeds Evidence supporting Accelerated Approval for Therapies Targeting Cancer .....                                                                                                                                                  | 195 |
| a.  | Tukysa Comparison - “Some is Enough” .....                                                                                                                                                                                                             | 197 |
| b.  | Opdivo’s 7% Increase in OS .....                                                                                                                                                                                                                       | 199 |
| c.  | Farydak’s 3.8 Month OS Data in 25 People.....                                                                                                                                                                                                          | 200 |
| d.  | Heterogeneous NTRK gene fusion Cancer Therapies.....                                                                                                                                                                                                   | 201 |
| e.  | Pemazyre (pemigatinib) for cholangiocarcinoma .....                                                                                                                                                                                                    | 202 |
| f.  | Temozolomide.....                                                                                                                                                                                                                                      | 202 |
| 2.  | Other Oncology Approvals .....                                                                                                                                                                                                                         | 204 |
| C.  | Despite Limitations with Bounded Scales and MCID, NurOwn Data are as Clinically Meaningful for ALS just as Brineura was for Batten Disease .....                                                                                                       | 207 |
| II. | NurOwn Meets Regulatory Thresholds for Approval With A Phase 4 Post-Marketing Study and Patients’ Mandatory Participation in a Biorepository and Natural History Database .....                                                                        | 210 |
| A.  | Substantial Evidence Supports NurOwn’s Approval.....                                                                                                                                                                                                   | 211 |
| 1.  | Expert KOL Neurologists, Statisticians Opined that NurOwn Works .....                                                                                                                                                                                  | 212 |
| 2.  | Existing Trial Data Supports Approval under “Totality of the Evidence” Protocol More Appropriate for Rare Disease Trials.....                                                                                                                          | 213 |
| 3.  | Post Hoc Data Can and Has Been Used to Support Drug Approvals in ALS .....                                                                                                                                                                             | 214 |
| B.  | New Respiratory Data Demonstrates a Clinically Meaningful Slowing in Time-to-NIV and is Reasonably Likely to Predict an Impact on Mortality. ....                                                                                                      | 216 |
| 1.  | Typical Respiratory Decline .....                                                                                                                                                                                                                      | 217 |
| 2.  | Therapies Approved Using Vital Capacity .....                                                                                                                                                                                                          | 217 |
| a.  | Idiopathic Pulmonary Fibrosis .....                                                                                                                                                                                                                    | 217 |
| b.  | Nexvazyme for Pompe disease .....                                                                                                                                                                                                                      | 218 |
| C.  | NurOwn’s Biomarker Evidence And Survival Evidence Are “Reasonably Likely To Predict A Clinically Meaningful Impact” on a Broader Population of People with ALS and thus Support Accelerated Approval with a Phase 4 Post-Marketing Biorepository. .... | 219 |
| 1.  | Intermediate Endpoint – Survival and Respiratory Data.....                                                                                                                                                                                             | 219 |
| 2.  | Surrogate Endpoint – Objective Biomarker Data is Reasonably Likely to Predict a Clinically Meaningful Benefit.....                                                                                                                                     | 220 |
| a.  | Neurofilament Light in EAP. ....                                                                                                                                                                                                                       | 221 |

|      |                                                                                                                                                                                                         |     |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| b.   | Two Dozen First-in-Class CSF Biomarkers. ....                                                                                                                                                           | 222 |
| D.   | RWE, RWD, PROs & Unblinded Patient Experience Buttress the<br>“Totality of the Evidence” and are Supporting Evidence that NurOwn Works.....                                                             | 222 |
| 1.   | FDA Committed to Use RWE from EAPs and Practice Settings .....                                                                                                                                          | 223 |
| 2.   | Congress Clearly Intended that the FDA Consider Both Real-world<br>Evidence and Patient Experiences when Making Efficacy Decisions. ....                                                                | 224 |
| 3.   | People who Received NurOwn Repeatedly Experienced “Clinically Meaningful”<br>Improvements in Function .....                                                                                             | 228 |
| 4.   | NurOwn Had a Dose-Dependent Response .....                                                                                                                                                              | 229 |
| E.   | FDA has Repeatedly Promised to Exercise Regulatory Flexibility in ALS .....                                                                                                                             | 230 |
| F.   | NurOwn Meets Conditional Approval Threshold of a “Plausible Mechanism<br>of Action” in a Heterogeneous Terminal Rare Disease with a Critical Unmet Need .....                                           | 233 |
| G.   | Mesenchymal Stem Cells & Neurotrophic Factors Demonstrate A Plausible<br>Mechanism of Action to Treat ALS, and NurOwn Uses a Plausible Method<br>Of Delivery to Avoid Blood Brain Barrier Hurdles. .... | 234 |
| 1.   | Neurotrophic Growth Factors have a Plausible Mechanism of<br>Action if the Method of Delivery Can Avoid the Problems with the<br>Blood Brain Barrier. ....                                              | 234 |
| 2.   | Stem Cell Research has Demonstrated a Plausible Mechanism of<br>Action in Multiple Neurological Diseases and Conditions with<br>Critical Unmet Needs. ....                                              | 236 |
| a.   | Stem Cell Research in ALS Showed Some Efficacy in Animal<br>Models and Demonstrated a Plausible Mechanism of Action<br>Two Decades Ago. ....                                                            | 236 |
| b.   | Stem Cells Showed Efficacy in Some People with ALS .....                                                                                                                                                | 237 |
| c.   | Stem Cells Showed Efficacy in Some Human Studies in<br>Neurodegenerative Diseases .....                                                                                                                 | 238 |
| d.   | Stem Cells Showed Efficacy in Human Studies of Spinal<br>Cord Injuries, Demonstrating a Plausible Mechanism of Action.....                                                                              | 239 |
| 3.   | NurOwn’s Plausible Mechanism of Action Demonstrated in MS.....                                                                                                                                          | 240 |
| III. | Petitioners are Asking the FDA to Consider Additional Risks In Its Risk-Benefit Assessment.....                                                                                                         | 242 |
| A.   | Risk Assessment must include the Risk of Type II Errors that Cause<br>Irreparable Harm to People with ALS.....                                                                                          | 242 |
| B.   | Risk Assessment must be Adjusted in 100% Fatal Rare Diseases.....                                                                                                                                       | 245 |
| C.   | Risk Assessment must include the Risk of People Going Outside<br>the US to get Treatments. ....                                                                                                         | 247 |

|     |                                                                                                                                                                                                                       |     |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1.  | Medical Tourism to Stem Cell Clinics Abroad .....                                                                                                                                                                     | 248 |
| 2.  | NP001 Story, Sodium Chlorite Substitute and Two Decades of Delays .....                                                                                                                                               | 250 |
| a.  | The Trial Participants’ Experience & RWD on Patients Like Me.....                                                                                                                                                     | 251 |
| b.  | NP001 - The Science and Regulatory Saga .....                                                                                                                                                                         | 252 |
| D.  | FDA should Exercise the Utmost of Regulatory Flexibility when the<br>Investigational Therapy is to Treat a Terminal, Service-Related Disease<br>that Veterans Get from Risking Their Lives to Serve our Country. .... | 255 |
| IV. | Petitioners are Asking FDA-CBER to Consider Additional Benefit of a Broad Phase 4<br>Biorepository and Natural History Database To Advance ALS Research &<br>Drug Development .....                                   | 257 |
| A.  | CSF Biomarkers .....                                                                                                                                                                                                  | 258 |
| B.  | Heterogeneity .....                                                                                                                                                                                                   | 258 |
| C.  | GWAS and Variants of Uncertain Significance.....                                                                                                                                                                      | 261 |
| 1.  | Example: SETX Variants Possibly Associated with ALS .....                                                                                                                                                             | 261 |
| 2.  | ALS VUS not Submitted to ClinVar .....                                                                                                                                                                                | 263 |
| 3.  | Polygenic Risk Factors, VUS and Repurposed Therapies.....                                                                                                                                                             | 263 |
| D.  | A Phase 4 Biorepository could Collect Exposome and Toxicology Data<br>Missed by the old CDC Registry.....                                                                                                             | 264 |
| 1.  | Gene-Time-Environment (GTE) Hypothesis .....                                                                                                                                                                          | 265 |
| 2.  | ALS Clusters across the US .....                                                                                                                                                                                      | 267 |
| 3.  | ALS Clusters in the Military .....                                                                                                                                                                                    | 269 |
| 4.  | Concussions and Repeated Sub-concussive TBIs .....                                                                                                                                                                    | 272 |
| 5.  | Case Study: Kade Simons.....                                                                                                                                                                                          | 273 |
| 6.  | Case Study: Jamie Rose Berry.....                                                                                                                                                                                     | 275 |
| a.  | Jamie’s Exposure to Mercury Mines and Smelters .....                                                                                                                                                                  | 275 |
| b.  | Jamie’s HFE Mutation, Manganese and Heavy Metal Exposures .....                                                                                                                                                       | 277 |
| c.  | The Science of ErbB4 and NRG1.....                                                                                                                                                                                    | 277 |
| i.  | Zonisamide Therapy for Rare ErbB4 Mutation?.....                                                                                                                                                                      | 278 |
| ii. | ErbB4 - Loss of Function Variants.....                                                                                                                                                                                | 280 |
| 7.  | Prospective Studies .....                                                                                                                                                                                             | 282 |

|    |                                                                                                                                       |            |
|----|---------------------------------------------------------------------------------------------------------------------------------------|------------|
| E. | New ALS Biorepositories can Store all Biosamples from a NurOwn Post-Marketing Study .....                                             | 284        |
| 1. | The EU & UK have the Largest Biorepositories and Natural History Studies....                                                          | 284        |
| 2. | New ALL-ALS Biorepository has the Infrastructure to Store Phase 4 Biosamples .....                                                    | 285        |
| V. | This Citizens’ Petition is our Only Recourse as the FDA Has Failed to Act<br>Despite our Myriad of Efforts Over the Last Decade. .... | 286        |
| A. | The 2021 Emails after FDA told Brainstorm the Data was Insufficient for a BLA.....                                                    | 288        |
| B. | The Improper FDA Statement commenting on the NurOwn Data .....                                                                        | 289        |
| C. | The Unintended Consequence of the FDA’s Improper Statement.....                                                                       | 290        |
|    | <b>CLOSING .....</b>                                                                                                                  | <b>291</b> |

**GRAPHICS**  
**Table of Contents**

1. Survival Data - NurOwn Phase 3 EAP Data thru June 2025
2. NurOwn's "Totality of the Evidence" from Phase 3 and EAP
3. ALS Heterogeneity
4. ALS Cellular Heterogeneity
5. Answer ALS Study FVC & Slope diagram - Slow & Fast Progressors
6. ALS Heterogeneity by Site of Onset
7. Answer ALS Study Figure 5 - Biological Pathways in ALS
8. Answer ALS Trajectory of Slope/Progression
9. EAP KM Survival Curve compared to Matched Controls
10. EAP Trial Design
11. Summary EAP Trach-Free Survival Data
12. EAP Trach-Free Survival Data
13. NurOwn's NEW Trach-free Survival versus Median ALS Natural History - Summary
14. NurOwn's Trach-free Survival vs Median ALS Natural History - by Participant
15. NurOwn's Trach-free Survival vs Median ALS Natural History - Bulbar Onset
16. NurOwn's Trach-free Survival vs Median ALS Natural History – Limb Onset
17. NurOwn's Time-to-NIV
18. NurOwn's NfL Change from Baseline Table
19. ALSFRS-R scale with four Domains and 12 Questions
20. C-Path's Discussion regarding Clinical Outcome Assessments in ALS
21. Baseline Scores and Floor Effect in Other ALS Trials
22. Heterogeneity - Limb Onset by UMN and LMN Subtypes
23. Studies re Non-Dominant Hand Onset Misleading Clinicians
24. Impact of Non-Dominant Hand Onset on Clinical Trial Outcomes
25. Some NurOwn Phase 3 Participants with Non-Dominant Hand Onset
26. Clinical Meaningfulness of One Point Change on ALSFRS-R
27. Dr. Jeremy Shefner Explaining that ALSFRS-R Slope is Linear
28. Genes & SNPs Tested in NurOwn Trial
29. NurOwn Phase 3a Trial Design
30. NurOwn's Impact on Early Progression Subgroup of ALSFRS-R  $\geq 35$
31. Totality of the Evidence: Multiple Endpoints in Subgroup of ALSFRS-R  $\geq 35$
32. Totality of the Evidence:- Multiple Domains in Subgroup of ALSFRS-R  $\geq 35$
33. Floor Effect Impact at Baseline ALSFRS-R Cut-points
34. Floor Effect Subgroup Consistent with Pre-specified ALSFRS-R  $\geq 35$  Subgroup

35. Totality Of Evidence in Floor Effect Subgroup Consistent Across Endpoints
36. Totality Of Evidence in Floor Effect Subgroup Consistent Across Domain Subscales
37. Totality Of Evidence in Floor Effect Subgroup Consistent Across Endpoints
38. Secondary Endpoints by Cut-point  $\geq 26$  to  $\geq 35$
39. Primary Endpoint: No Floor Effect Subgroup and  $\geq 27$  Subgroup
40. Secondary Endpoint: No Floor Effect Subgroup and  $\geq 27$  Subgroup
41. Tofersen Change from Baseline at 28 weeks
42. Tofersen vs. NurOwn: Change from Baseline at 28 weeks
43. NurOwn Primary & Secondary Endpoint  $\geq 35$  Demonstrating Stabilization
44. NurOwn's Phase 2 Trial Results
45. NurOwn's Phase 2 Trial Results  $\geq 100\%$  Improvement in Slope in Rapid Progressors
46. Tofersen's Phase 3 Survival Data in A5V Rapid Progressors
47. Eric Stevens' ALSFRS-R Phase 3 and EAP
48. Josh Smith's ALSFRS-R scores in Phase 3 and EAP
49. Kade Simons' ALSFRS-R scores in Phase 3 and EAP
50. Lesley Krummel's ALSFRS-R scores in Phase 3 and EAP
51. Justin Rogers' Bulbar Survival versus Median Survival from Diagnosis
52. Right to Try Bill Signing with Matt Bellina and Nicole Cimbura
53. Tara Collazo's ALSFRS-R scores by Domain
54. Military Medicine Study regarding Post 9/11 Veterans and ALS
55. Matt Bellina's Real-World Data
56. WLWT Broadcast: Fighting for Their Lives
57. Time-to-Event Data in ALS
58. Time-to-NIV
59. Josh Smith's FVC Tests 2020 Pre-EAP vs. 2021 Post-EAP
60. FVC Tests 2021 vs. 2022 Post-EAP for Eric Stevens and Phil Green
61. NurOwn CSF Biomarkers across 3 Primary Pathways
62. NurOwn CSF Biomarkers PCA across 3 Primary Pathways
63. NurOwn Biomarker Changes (Table S3 in Muscle & Nerve)
64. Totality of CSF Biomarker Evidence Supports Mechanism of Action
65. FDA Slides about Neurofilament Light from Tofersen AdComm
66. NurOwn's Neurofilament Light Results from Phase 3
67. NurOwn's Neurofilament Light Results from Phase 3 and EAP
68. NurOwn's Neurofilament Light Results from Early Start vs Delayed Start in EAP
69. NurOwn's Neurofilament Light Results - Percentage of Change Bar Chart
70. NurOwn's Neurofilament Light Results - Percentage of Change - by Participant
71. Neurofilament Light Pattern Changes - NurOwn vs. Tofersen
72. UNC13A and the 66 Mis-splicing Genes in ALS
73. UNC13A in ALS GWAS

74. UNC13A (A/C) Responder Analysis in NurOwn Phase 3 Trial
75. FDA's Presentation Slide of Neurotrophic Factors for ALS Treatments
76. Neurotrophic Factors for ALS: BDNF, GDNF, EGF and HGF
77. NurOwn's Phase 3B Trial Design
78. NurOwn Timeline
79. Tukysa Partial Response
80. Vitrakvi
81. ALS KOL, Mayo's Dr. Windebank AdComm Testimony that NurOwn Works
82. NurOwn's Totality of the Evidence: p-values by endpoint and cut-point
83. Post Hoc Data Used in all Four ALS Drug Approvals
84. Tofersen Post Hoc Data Accepted
85. PFDD – Patient Experience
86. C-Path's COAs: Patient Experience and PFDD
87. Phase 2 and 3 Data Confirms Some Patients Halted Progression
88. FDA's Regulatory Flexibility Slide from Tofersen AdComm
89. Plausible MOA: Stem Cell Trials in ALS
90. Plausible MOA: Stem Cell Trials in Other Neurodegenerative Diseases
91. Risk-Benefit: Risk of Type II Errors
92. Heterogeneity in ALS Trials and Impact on Trial Outcomes
93. Heterogeneity: SETX-VUS
94. Gene-Time-Environment Hypothesis
95. Genetic Risk and ALS Exposome
96. Genetic Risk and ALS Exposome Natural History Database
97. Prospective ALS Exposome Natural History Database
98. NurOwn Phase 3 Trial Participant Betsy McCormick on Cancelled EAP